Hangzhou Hospital Staff Cohort

Cardiovascular Diseases Clinical Trial

— HHSC  

Official title:

Hangzhou Hospital Staff Cohort

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04910321
• Other study ID #: 20201221ZJS001
• Status: Active, not recruiting
• Start date: December 30, 2020
• Est. completion date: December 31, 2029

Study information

• Verified date: April 2022
• Source: Westlake University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The Hangzhou Hospital Staff Cohort (HHSC) is a prospective cohort study among staffs from three hospitals located in Hangzhou, China, including the Hangzhou First People's Hospital, Hangzhou Women's Hospital, and Hangzhou Red Cross Hospital. Participants recruitment and baseline survey including anthropometric, lifestyle and clinical measurement, as well as biological samples collection are initiated in January 2021. Recruited hospital staff are followed up every year during the medical examination organized by their employer. The primary aim of the HHSC study is to investigate the prospective associations of diet, physical activities, sleep, and other lifestyle factors with the long-term metabolic health of the hospital staffs. The secondary aim of the HHSC study is to integrate multi-omics data including genomics, metabolomics, proteomics and microbiome by a machine learning algorithm, to probe into the complex mediating roles of gene, metabolism and gut microbiota linking lifestyle factors with metabolic health.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3000
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2029
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants aged 18 years or older

• Serving staffs of designated hospitals

Exclusion Criteria:

• Participants with cancer

• Participants with other serious medical disorders

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes Mellitus
• Metabolic Syndrome

Intervention

Other:
• diet, physical activities, sleep
lifestyle factors

Locations

Country	Name	City	State
China	Hangzhou First People's Hospital	Hangzhou	Zhejiang

Sponsors (4)

Lead Sponsor	Collaborator
Westlake University	First People's Hospital of Hangzhou, Hangzhou Red Cross Hospital, Hangzhou Women's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L	Fasting blood glucose is measured every year during follow-up	3 years after enrollment
Primary	Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L	Fasting blood glucose is measured every year during follow-up	6 years after enrollment
Primary	Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L	Fasting blood glucose is measured every year during follow-up	9 years after enrollment
Secondary	Change of body mass index	Participants' body weight and height was measured to calculate body mass index every year during follow-up	Change from baseline at 3 years
Secondary	Change of body mass index	Participants' body weight and height was measured to calculate body mass index every year during follow-up	Change from baseline at 6 years
Secondary	Change of body mass index	Participants' body weight and height was measured to calculate body mass index every year during follow-up	Change from baseline at 9 years